Pulse - CAR-T vs Auto-T: who is in the relapsed or refractory large b-cell lymphoma treatment winner’s circle?
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
To provide education to pharmacists regarding the difference between CAR-T vs Auto-T therapy in Oncology Practice.
Target Audience
Pharmacist
Learning Objectives
1. Review the role of autologous stem cell transplant as standard second-line therapy in relapsed or refractory large Bcell lymphoma
2. Describe the current role of CAR T-cell therapy in relapsed or refractory large B-cell lymphoma
3. Discuss emerging literature advancing the use of CAR T-cell therapy in the second line setting
Additional Information
Attachment | Size |
---|---|
![]() | 861.76 KB |
![]() | 15.75 KB |
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
To provide education to pharmacists regarding the difference between CAR-T vs Auto-T therapy in Oncology Practice.
Taylor Werner, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.